Alveogene

Alveogene is a biotech company in United Kingdom, founded in 2022. It has 1 recorded funding round, most recently a Seed in September 2023.

Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy

Employees
1–10
Founded
2022
Business Model
B2B
Last Round
SeedSep 2023
Rounds
1

Indexed holds 1 funding round and 2 investors for this company. The full record is or through the API.

About

AlveoGene develops inhaled gene therapies that aim to treat rare respiratory diseases by delivering therapy directly to the lungs. Its proprietary InGenuiTy lentiviral platform, licensed from the UK Respiratory Gene Therapy Consortium, is designed for high transduction of lung epithelial cells via nebuliser or neonatal instillation and can be readministered without losing efficacy. The company was created by Oxford Science Enterprises, Harrington Discovery Institute, and Old College Capital with six GTC scientist co-founders, and is advancing candidates for conditions such as surfactant protein B deficiency.

Summary

It lists 1–10 employees. Its most recent funding was a Seed round in Sep 2023. Investors include Oxford Science Enterprises and Old College Capital.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
SeedSeed RoundSep 2023

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Alveogene on Indexed.vc
<a href="https://indexed.vc/companies/alveogene"><img src="https://indexed.vc/api/badge/company/alveogene" alt="Alveogene on Indexed.vc" width="260" height="76" /></a>